3-(2-chloroethyl)-7-methyl-5,6,7,8-tetrahydropyrido[4', 3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one | 281657-01-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: 3-(2-chloroethyl)-7-methyl-5,6,7,8-tetrahydropyrido[4', 3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one
• 英文别名: 3-(2-Chloroethyl)-7-methyl-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one；4-(2-chloroethyl)-11-methyl-8-thia-4,6,11-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),5-trien-3-one
• CAS: 281657-01-0
• 化学式: C₁₂H₁₄ClN₃OS
• 分子量: 283.782
• InChiKey: ZWMMNHGOCGSKGI-UHFFFAOYSA-N

物化性质

• 沸点：
  473.1±55.0 °C(predicted)
• 密度：
  1.51±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  64.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(2-chloroethyl)-7-methyl-5,6,7,8-tetrahydropyrido[4', 3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one 、 1-(4-氯-2-甲氧基苯基)哌嗪 在 N,N-二异丙基乙胺 、 sodium bromide 作用下， 以 N-甲基吡咯烷酮 为溶剂， 生成 3-{2-[4-(4-Chloro-2-methoxy-phenyl)-piperazin-1-yl]-ethyl}-7-methyl-5,6,7,8-tetrahydro-3H-pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4-one
  参考文献：
  名称：

  Synthesis and SAR of highly potent dual 5-HT1A and 5-HT1B antagonists as potential antidepressant drugs

  摘要：

  Novel 5-HT1 autoreceptor ligands based on the N-4-aryl-piperazinyl-N'-ethyl-5,6,7,8-tetrahydropyrido[4', 3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one core are described. Aiming at antidepressants with a novel mode of action our objective was to identify potent antagonists showing balanced affinities and high selectivity for the 5-HT1A and 5-HT1B receptors. Strategies for the development of dual 5-HT1A and 5-HT1B antagonists based on 1 and 2 as leads and the corresponding results are discussed. Isoquinoline analogue 33 displayed high affinity and an antagonistic mode of action for the 5-HT1A and the 5-HT1B receptors and was characterized further with respect to selectivity, electrically stimulated [H-3]5-HT release and in vivo efficacy. (c) 2005 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2005.04.077
• 作为产物：
  描述：

  3-(2-hydroxyethyl)-7-methyl-5,6,7,8-tetrahydropyrido[4', 3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one 在 氯化亚砜 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 2.0h， 以68%的产率得到3-(2-chloroethyl)-7-methyl-5,6,7,8-tetrahydropyrido[4', 3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one
  参考文献：
  名称：

  [DE] 3-SUBSTITUIERTE 3,4-DIHYDRO-THIENO[2,3-D]PYRIMIDIN-4-ON-DERIVATE, IHRE HERSTELLUNG UND VERWENDUNG
  [EN] 3-SUBSTITUTED 3,4-DIHYDRO-THIENO[2,3-D]PYRIMIDINE-4-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF
  [FR] DERIVES DE 3,4-DIHYDRO-THIENO[2,3-D]PYRIMIDIN-4-ONE 3-SUBSTITUES, LEUR PREPARATION ET LEUR UTILISATION

  摘要：

  该专利涉及3,4-二氢噻吩并[2,3-d]嘧啶-4-酮衍生物，其在3位被5元杂环芳基取代，可以与芳基或杂环芳基残基缩合，其中杂环芳基和可能的缩合芳基或杂环芳基残基可以独立地携带在C1-5-烷基，C1-5-烷氧基，C1-5-烷硫基，卤素，CN，卤代-C1-5-烷基，卤代-C1-5-烷氧基，羟基，-NH2，-N(R6)2，-NH(R6)，芳基，芳氧基，芳基烷基，芳基烷氧基和杂环芳基中选择的取代基上，其中取代基芳基，芳氧基，芳基烷基，芳基烷氧基和杂环芳基可以独立地携带在C1-5-烷硫基，卤素，CN，卤代-C1-5-烷基，卤代-C1-5-烷氧基，羟基，-NH2，-N(R6)2和-NH(R6)中选择的取代基上。此类衍生物的制备和用途，特别是用于治疗目的，例如治疗抑郁症，也有描述。

  公开号：

  WO2004055024A1

文献信息

• [DE] 3-SUBSTITUIERTE 3,4-DIHYDRO-THIENO[2,3-D]PYRIMIDIN-4-ON-DERIVATE, IHRE HERSTELLUNG UND VERWENDUNG<br/>[EN] 3-SUBSTITUTED 3,4-DIHYDRO-THIENO[2,3-D]PYRIMIDINE-4-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF<br/>[FR] DERIVES DE 3,4-DIHYDRO-THIENO[2,3-D]PYRIMIDIN-4-ONE 3-SUBSTITUES, LEUR PREPARATION ET LEUR UTILISATION
  申请人：ABBOTT GMBH & CO KG

  公开号：WO2004055024A1

  公开（公告）日：2004-07-01

  Die erfindung betrifft 3,4-Dihydro-thieno[2,3-d]pyrimidin-4-on-Derivate, die in 3-Position mit 5-gliedrigem Heteroaryl substituierte sind, das mit einem Aryl- oder Heteroarylrest kondensiert sein kann, wobei das Heteroaryl und gegebenenfalls der kondensierte Aryl- oder Heteroarylrest 1,2 oder 3 unabhängig voneinander unter C1-5-Alkyl, C1-5-Alkoxy, C1-5-Alkylthio, Halogen, CN, Halogen-C1-5-alkyl, Halogen-C1-5alkoxy, Hydroxy, -NH2, -N(R6)2, -NH(R6), Aryl, Aryloxy, Aralkyl, Aralkyloxy und Heteroaryl ausgewählte Substituenten tragen können, wobei die Substituenten Aryl, Aryloxy, Aralkyl, Aralkyloxy und Heteroaryl 1,2 oder 3 unabhängig voneinander unter C1-5-Alkythio, Halogen, CN, Halogen-C1-5-alkyl, Halogen-C1-5alkoxy, Hydroxy, -NH2, -N(R6)2 und -NH(R6) ausgewählte Substituenten tragen können. Die Herstellung und Verwendung dieser Derivate, insbesondere zu therapeutischen Zwecken, z.B. bei der Behandlulng von Depressionen, werden ebenfalls beschrieben.

  该专利涉及3,4-二氢噻吩并[2,3-d]嘧啶-4-酮衍生物，其在3位被5元杂环芳基取代，可以与芳基或杂环芳基残基缩合，其中杂环芳基和可能的缩合芳基或杂环芳基残基可以独立地携带在C1-5-烷基，C1-5-烷氧基，C1-5-烷硫基，卤素，CN，卤代-C1-5-烷基，卤代-C1-5-烷氧基，羟基，-NH2，-N(R6)2，-NH(R6)，芳基，芳氧基，芳基烷基，芳基烷氧基和杂环芳基中选择的取代基上，其中取代基芳基，芳氧基，芳基烷基，芳基烷氧基和杂环芳基可以独立地携带在C1-5-烷硫基，卤素，CN，卤代-C1-5-烷基，卤代-C1-5-烷氧基，羟基，-NH2，-N(R6)2和-NH(R6)中选择的取代基上。此类衍生物的制备和用途，特别是用于治疗目的，例如治疗抑郁症，也有描述。
• 3-Substituted 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof
  申请人：Bakker Margaretha

  公开号：US20060142317A1

  公开（公告）日：2006-06-29

  The invention relates to 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives which are substituted in position 3 by 5-membered heteroaryl which may be fused to an aryl or heteroaryl radical, where the heteroaryl and, if appropriate, the fused aryl or heteroaryl radical may have 1, 2 or 3 substituents selected independently of one another from C 1-5 -alkyl, C 1-5 -alkoxy, C 1-5 -alkylthio, halogen, CN, halo-C 1-5 -alkyl, halo-C 1-5 -alkoxy, hydroxy, —NH 2 , —N(R6) 2 , —NH(R6), aryl, aryloxy, aralkyl, aralkyloxy and heteroaryl, where the substituents aryl, aryloxy, aralkyl, aralkyloxy and heteroaryl may have 1, 2 or 3 substituents selected independently of one another from C 1-5 -alkyl, C 1-5 -alkoxy, C 1-5 -alkylthio, halogen, CN, halo-C 1-5 -alkyl, halo-C 1-5 -alkoxy, hydroxy, —NH 2 , —N(R6) 2 and —NH(R6). The preparation and use of these derivatives, especially for therapeutic purposes, e.g. for the treatment of depressions, are likewise described.

  本发明涉及3,4-二氢噻吩[2,3-d]嘧啶-4-酮衍生物，其在3位被5-成员杂环芳基取代，该杂环芳基可以与芳基或杂环芳基基团融合，其中该杂环芳基和（如适用）融合的芳基或杂环芳基基团可以具有1、2或3个取代基，这些取代基可独立地从C1-5-烷基、C1-5-烷氧基、C1-5-烷基硫基、卤素、CN、卤代C1-5-烷基、卤代C1-5-烷氧基、羟基、—NH2、—N(R6)2、—NH(R6)、芳基、芳氧基、芳基烷基、芳基烷氧基和杂环芳基中选择，其中芳基、芳氧基、芳基烷基、芳基烷氧基和杂环芳基的取代基可独立地从C1-5-烷基、C1-5-烷氧基、C1-5-烷基硫基、卤素、CN、卤代C1-5-烷基、卤代C1-5-烷氧基、羟基、—NH2、—N(R6)2和—NH(R6)中选择。同时还描述了这些衍生物的制备和使用，特别是用于治疗目的，例如用于治疗抑郁症。
• 3-substituted pyrido&lsqb;4′,3′:4,5&rsqb;thieno&lsqb;2,3-d&rsqb;pyrimidine derivatives, their preparation and their use
  申请人：BASF Aktiengesellschaft

  公开号：US06222034B1

  公开（公告）日：2001-04-24

  A 3-substituted 3,4,5,6,7,8-hexahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine compound of formula I wherein R1 is hydrogen, C1-C4-alkyl, acetyl or benzoyl, optionally substituted phenyl-C1-C4-alkyl, naphthyl-C1-C3-alkyl, phenyl-C2-C3-alkanone or a phenylcarbamoyl-C2-alkyl, R2 is optionally substituted phenyl, pyridyl, pyrimidyl or pyrazinyl, or an optionally substituted bicyclus wherein one of the two fused rings is a phenyl, a pyridyl, a pyrimidyl or a pyrazinyl ring, A is NH or oxygen, B is hydrogen or methyl, C is hydrogen, methyl or hydroxyl, X is nitrogen, Y is CH2, CH2—C2, CH2—C2—CH2 or CH2—CH, Z is nitrogen, C or CH, and the linkage between Y and Z is a single or a double bond, and n is 2, 3 or 4, or a physiologically tolerated salt thereof, and compositions comprising them and their use as antagonists of 5HT1B and 5HT1A and for the treatment of depression and related disorders.

  化合物I的式子为：其中R1是氢、C1-C4烷基、乙酰基或苯甲酰基，可选取取代苯基-C1-C4烷基、萘基-C1-C3烷基、苯基-C2-C3酮或苯基氨甲酰-C2烷基；R2是可选取取代苯基、吡啶基、嘧啶基或吡嗪基，或一个其中一个融合环为苯基、吡啶基、嘧啶基或吡嗪基的可选取取代的双环；A为NH或氧；B为氢或甲基；C为氢、甲基或羟基；X为氮；Y为CH2、CH2—C2、CH2—C2—CH2或CH2—CH；Z为氮、C或CH，且Y和Z之间的连接为单键或双键；n为2、3或4；或其生理耐受的盐；以及包含它们的组成物和它们作为5HT1B和5HT1A拮抗剂及治疗抑郁症和相关疾病的用途。
• USE OF BINDING PARTNERS FOR 5-HT5 RECEPTORS FOR THE TREATMENT OF NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS
  申请人：Garcia-Ladona Francisco Javier

  公开号：US20120196301A1

  公开（公告）日：2012-08-02

  The present invention relates to the use of binding partners for 5-HT5 receptors for the treatment of neuropathological, in particular neurodegenerative and/or neuropsychiatric, disorders, which can occur, in particular, in cerebral ischemia, stroke, epilepsy and seizures in general, chronic schizophrenia, other psychotic disorders, dementia, in particular Alzheimer's dementia, demyelinizing disorders, in particular multiple sclerosis, and brain tumors. The invention also relates to processes for the identification and characterization of such binding partners, in particular in the form of screening processes.

  本发明涉及使用与5-HT5受体结合的配体治疗神经病理学，特别是神经退行性和/或神经精神疾病，这些疾病可以在脑缺血、中风、癫痫和一般性抽搐、慢性精神分裂症、其他精神疾病、痴呆，特别是阿尔茨海默病、脱髓鞘性疾病，特别是多发性硬化症和脑肿瘤中发生。本发明还涉及用于鉴定和表征此类配体的过程，特别是以筛选过程的形式。
• Verwendung von 5-ht5-liganden zur behandlung neurodegenerativer und neuropsychiatrischer störungen
  申请人：Abbott GmbH & Co. KG

  公开号：EP2266570A1

  公开（公告）日：2010-12-29

  Die vorliegende Erfindung betrifft die Verwendung von Bindungspartnern für 5-HT5-Rezeptoren zur Behandlung neuropsychiatrischer Störungen wie Schizophrenie und Psychosen.

  本发明涉及使用 5-HT5 受体的结合伙伴治疗神经精神疾病，如精神分裂症和精神病。